AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01638676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
Study NCT04454749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Mesurement of E2, P4, LH, FSH hormones
Study NCT04454749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Follicular measurement and endometrium measurement
Study NCT04929691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP helmet
Description: helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
Study NCT04929691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care non-helmet based CPAP ventilation
Description: Standard of care ventilation without helmet-based CPAP
Study NCT03463213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE Tribe
Description: Social network-based peer-facilitated intervention to promote adoption of health behavior
Study NCT00713557 — intervention group
Intervention type: DEVICE
Intervention: drug-eluting stent
Description: drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
Study NCT00713557 — intervention group
Intervention type: DRUG
Intervention: Tirofiban
Description: upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
Study NCT01864486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Retinal Implant System
Study NCT01336257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEBASTIAN Clinical Decision Support System (CDSS)
Description: SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
Study NCT04369586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meplazumab for injection
Description: single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
Study NCT03049579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Weiquan Yogurt without probiotics
Description: 150 ml daily consumption for a total of 12 weeks
Study NCT02850965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Study NCT01248988 — intervention group
Intervention type: OTHER
Intervention: Synflorix™ Data collection
Description: Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
Study NCT01101282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) mask therapy
Description: PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
Study NCT04370587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
Study NCT02850965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Study NCT04370587 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: T3011 + pembrolizumab
Description: T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
Study NCT00789152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine 5 mg daily x 8 days
Study NCT00789152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocetirizine
Description: levocetirizine 5 mg daily x 8 days
Study NCT00000428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline 25 mg po
Study NCT00000428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline plus Fluoxitine
Description: Amitriptyline 25 mg po plus Fluoxitine 20 mg po
Study NCT02463084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Diet
Description: a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
Study NCT02463084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Diet
Description: a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
Study NCT00620867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg oral tablet three time daily with meals for 6 weeks
Study NCT04369586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT00620867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Study NCT00620867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo orally for 6 weeks
Study NCT00464620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: oral agent, continuous dosing, Cycles = 28 days
Study NCT02868775 — intervention group
Intervention type: PROCEDURE
Intervention: cystoscopy, bladder hydrodistention and bladder biopsy
Study NCT04194034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG6002
Description: Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient.
Study NCT04194034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine (5-FC)
Description: Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between.
Study NCT00306215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX282-B
Description: CCX282-B or placebo capsules
Study NCT04235985 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Chlorhexidine Gluconate with HUBS
Description: 4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
Study NCT02852538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEW FED TR
Description: NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
Study NCT04489563 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: i-ACT
Description: Performing exercises with an adapted motion detection device (i.ACT) for 20-30 minutes.
Study NCT02423876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Description: Receive epidural placement. Standard epidural medications and dosage are as follows:~* 0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~* 3 mL/hr RN bolus, to be used as needed based on pain ratings~* 3 mL/30 minutes patient bolus, which is available on patient demand.
Study NCT02423876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Complication Management and Prevention
Description: Undergo ERP
Study NCT02423876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Complication Management and Prevention
Description: Undergo ERP
Study NCT02423876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain Therapy
Description: Undergo ERP
Study NCT02423876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pain Therapy
Description: Undergo ERP
Study NCT01294267 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Circulatory Support System
Description: Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
Study NCT02742480 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Study NCT01048476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lutein
Description: Dietary Supplement: 20mg Lutein; daily supplementation one year
Study NCT01048476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Dietary Supplement: 10mg Lutein; daily supplementation one year
Study NCT01048476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dietary Supplement: placebo; daily supplementation one year
Study NCT01048476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein and zeaxanthin
Description: Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
Study NCT03322995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First-line Chemotherapy
Description: The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.
Study NCT03322995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second-line Chemotherapy
Description: Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.
Study NCT03322995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 50.4 Gy in 28 fractions.
Study NCT03778541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
Study NCT03778541 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
Study NCT03778541 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hypofractionated radiotherapy
Description: the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
Study NCT02020694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT02020694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for vitamin D)
Study NCT02996136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flu Symptoms
Description: Flu Symptoms
Study NCT04319549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine irrigant
Description: Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
Study NCT04319549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite irrigant
Description: NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
Study NCT03789071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: External ultrasound evaluation of the airway
Description: Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
Study NCT01951170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
Study NCT00557492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (bevacizumab)
Description: 10 mg/kg, days 1, 15, 29 and 43
Study NCT00557492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar (Gemcitabine)
Description: On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
Study NCT00557492 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiotherapy
Description: 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
Study NCT01884805 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Monocular Adaptive Optics Visual Simulator (AOVIS-I)
Description: The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
Study NCT04541797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
Study NCT04541797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
Study NCT04541797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Stress Cardiac Magnetic Resonance
Description: Imaging: All patients will have stress CMR examinations at recruitment.
Study NCT04541797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress Cardiac Magnetic Resonance
Description: Imaging: All patients will have stress CMR examinations at recruitment.
Study NCT03890848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wechat application reminder intervention
Description: precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
Study NCT03890848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine guidance during discharge
Description: rehabilitation exercise guidance during routine discharge
Study NCT00872872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT/3TC 2 weeks after delivery
Description: AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
Study NCT00872872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC 2 weeks after delivery
Description: AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
Study NCT04048681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet soda
Description: 12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
Study NCT04048681 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular soda
Description: 12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
Study NCT04048681 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Carbonated Water
Description: 12oz can of carbonated water (sparking water, selzter water) unflavored
Study NCT00545519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymoglobulin
Study NCT02941484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early oral intake
Description: early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
Study NCT02383810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03448497 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study NCT01308905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLT-PET
Description: PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
Study NCT04479553 — intervention group
Intervention type: DRUG
Intervention: Qizhi Tongluo Capsules
Description: Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
Study NCT03718312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamping with pre-conditioning (PCl)
Description: PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice.
Study NCT01725295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NST
Description: A form of physical therapy
Study NCT01725295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Study NCT02742480 — intervention group
Intervention type: DRUG
Intervention: Acenocoumarol
Study NCT04031157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictix Antidepressant
Description: Predictix Antidepressant guided treatment
Study NCT04306302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC10V
Description: Participants will receive a single IM injection of ExPEC10V.
Study NCT04306302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single IM injection of matching placebo.
Study NCT00992914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sympathetic nerve block with 1% lidocaine 1-2 ml
Description: Stellate Ganglion Injection
Study NCT00992914 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superficial subcutaneous injection
Description: Superficial subcutaneous injection with saline
Study NCT04316286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tele-multidisciplinary care
Description: Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
Study NCT04316286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone or equivalent
Description: Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous